AIM
GLMD icon

ARK Investment Management’s Galmed Pharmaceuticals GLMD Stock Holding History

ARK Investment Management’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,290
Closed -$1.11M – 226
2020
Q2 		$1.11M Buy
1,290
+800
+163% +$675K 0.01% 154
2020
Q1 		$305K Sell
490
-14
-3% -$13.3K 0.01% 156
2019
Q4 		$525K Buy
504
+101
+25% +$86.8K 0.01% 131
2019
Q3 		$347K Buy
403
+64
+19% +$64.2K 0.01% 178
2019
Q2 		$448K Buy
339
+40
+13% +$51.6K 0.01% 146
2019
Q1 		$439K Buy
299
+72
+32% +$105K 0.01% 147
2018
Q4 		$279K Buy
227
+28
+14% +$48.9K 0.01% 146
2018
Q3 		$487K Buy
+199
New +$466K 0.01% 147

Other funds holding GLMD

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

ARK Investment Management's GLMD Position: Q3 2020 in Review

ARK Investment Management sold out of Galmed Pharmaceuticals (GLMD) in Q3 2020, closing a stake of 1,290 shares — an estimated $1.11M sold.

ARK Investment Management first reported a position in GLMD in Q3 2018 and held it in 8 quarters. The position peaked at $1.11M in Q2 2020. 24 funds tracked by Wall St. Rank hold GLMD as of Q3 2020.

  • ARK Investment Management reported no remaining Galmed Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • ARK Investment Management sold 1,290 Galmed Pharmaceuticals shares in Q3 2020, an estimated $1.11M.
  • ARK Investment Management first reported a position in Galmed Pharmaceuticals in Q3 2018 and held it in 8 quarters.
  • ARK Investment Management's Galmed Pharmaceuticals position peaked at $1.11M in Q2 2020.
  • 24 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2020.

Based on ARK Investment Management's 13F filing for Q3 2020, filed 30 Oct 2020.